Thursday, September 21, 2006 Capitol
Hill Watch
Senate HELP Committee Approves Von Eschenbach
Nomination To Head FDA; Some Senators Say They Will Place Hold on
Nomination
The Senate Health, Education, Labor and Pensions Committee on
Wednesday by voice vote approved President Bush's nomination of acting FDA Commissioner Andrew von
Eschenbach to permanently head the agency, but potential holds to a full
Senate vote on the nomination remain, the New York Times reports (Harris,
New York Times, 9/21). Sen. Jim DeMint (R-S.C.) has said he
would place a hold on the nomination unless steps are taken to remove Danco Laboratories'
medical abortion drug Mifeprex from the market. The drug has been linked
to eight deaths and "many injuries" since it was approved by FDA, CQ
Today reports. Sen. David Vitter (R-La.) also has said he would place
a hold on the nomination until the Bush administration allows U.S.
residents to purchase U.S.- made prescription drugs from abroad (CQ
Today, 9/15). DeMint in a statement released on Wednesday said, "I believe a
qualified FDA nominee would publicly discourage the use of [Mifeprex] and
take immediate steps to suspend the drug until a full investigation can be
completed. Dr. von Eschenbach has now been acting FDA commissioner for a
year, yet he has done nothing to publicly discourage the use of this
deadly drug" (Watts, Dow Jones, 9/20). Senate HELP Committee
Chair Michael Enzi (R-Wyo.) said he and Sen. Edward Kennedy (D-Mass.), the
ranking member on the panel, would be working "virtually full time" until
the Senate convenes next week to persuade senators to approve the
nomination (New York Times, 9/21). A spokesperson for DeMint
said that while the senator "continues to work with the administration,
the FDA and the (HELP) committee," he will maintain his hold on the
nomination (Young, The Hill, 9/21).